<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Nelson Pediatrics â€” Part XIV: Rheumatic Diseases of Childhood</title>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;700;900&family=DM+Sans:wght@300;400;500;600&family=DM+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
  :root {
    --bg:#0d1117; --surface:#161b22; --surface2:#1c2333; --border:#30363d;
    --accent:#f472b6;   /* pink/rose â€” connective tissue/rheum feel */
    --accent2:#fb923c;  /* orange */
    --accent3:#34d399;  /* green */
    --accent4:#fbbf24;  /* amber */
    --danger:#f87171;   /* red */
    --purple:#a78bfa;   /* purple */
    --sky:#60a5fa;      /* blue */
    --text:#e6edf3; --text-muted:#8b949e; --text-dim:#484f58;
  }
  *{margin:0;padding:0;box-sizing:border-box}
  body{background:var(--bg);color:var(--text);font-family:'DM Sans',sans-serif;font-weight:300;line-height:1.75;min-height:100vh}
  body::before{content:'';position:fixed;inset:0;background-image:url("data:image/svg+xml,%3Csvg viewBox='0 0 256 256' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='n'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.9' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23n)' opacity='0.04'/%3E%3C/svg%3E");pointer-events:none;z-index:0;opacity:.4}
  .pw{position:relative;z-index:1;max-width:960px;margin:0 auto;padding:0 24px 80px}

  /* HERO */
  .hero{padding:72px 0 48px;border-bottom:1px solid var(--border);margin-bottom:48px;position:relative;overflow:hidden}
  .hero::after{content:'XIV';position:absolute;right:-8px;top:0;font-family:'Playfair Display',serif;font-size:140px;font-weight:900;color:var(--border);line-height:1;pointer-events:none;user-select:none}
  .hero-tag{display:inline-flex;align-items:center;gap:8px;background:rgba(244,114,182,.1);border:1px solid rgba(244,114,182,.3);color:var(--accent);font-family:'DM Mono',monospace;font-size:11px;letter-spacing:.12em;text-transform:uppercase;padding:5px 12px;border-radius:4px;margin-bottom:20px}
  .hero-tag::before{content:'';width:6px;height:6px;border-radius:50%;background:var(--accent);animation:pulse 2s ease-in-out infinite}
  @keyframes pulse{0%,100%{opacity:1;transform:scale(1)}50%{opacity:.4;transform:scale(.8)}}
  .hero h1{font-family:'Playfair Display',serif;font-size:clamp(24px,4vw,46px);font-weight:900;line-height:1.1;margin-bottom:12px}
  .hero h1 span{color:var(--accent)}
  .hero-sub{font-size:15px;color:var(--text-muted);max-width:560px;margin-bottom:28px}
  .hero-meta{display:flex;gap:24px;flex-wrap:wrap}
  .meta-pill{display:flex;align-items:center;gap:6px;font-size:12px;color:var(--text-muted);font-family:'DM Mono',monospace}
  .meta-pill .dot{width:8px;height:8px;border-radius:50%}

  /* SEARCH */
  .search-bar{position:sticky;top:0;z-index:100;background:rgba(13,17,23,.93);backdrop-filter:blur(12px);border-bottom:1px solid var(--border);padding:12px 0;margin-bottom:36px}
  .search-inner{max-width:960px;margin:0 auto;padding:0 24px;display:flex;align-items:center;gap:12px}
  .search-input{flex:1;background:var(--surface);border:1px solid var(--border);border-radius:8px;padding:8px 14px 8px 36px;color:var(--text);font-family:'DM Sans',sans-serif;font-size:14px;outline:none;transition:border-color .2s;background-image:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='16' height='16' viewBox='0 0 24 24' fill='none' stroke='%238b949e' stroke-width='2'%3E%3Ccircle cx='11' cy='11' r='8'/%3E%3Cpath d='m21 21-4.35-4.35'/%3E%3C/svg%3E");background-repeat:no-repeat;background-position:10px center}
  .search-input:focus{border-color:var(--accent)}
  .search-input::placeholder{color:var(--text-dim)}
  .chapter-count{font-family:'DM Mono',monospace;font-size:11px;color:var(--text-muted);white-space:nowrap}

  /* STATS */
  .stats-strip{display:grid;grid-template-columns:repeat(auto-fit,minmax(185px,1fr));gap:12px;margin-bottom:48px}
  .stat-card{background:var(--surface);border:1px solid var(--border);border-radius:10px;padding:16px 18px;transition:border-color .2s,transform .2s}
  .stat-card:hover{border-color:var(--accent);transform:translateY(-2px)}
  .stat-label{font-family:'DM Mono',monospace;font-size:10px;text-transform:uppercase;letter-spacing:.1em;color:var(--text-muted);margin-bottom:6px}
  .stat-value{font-family:'Playfair Display',serif;font-size:19px;font-weight:700;color:var(--accent)}
  .stat-desc{font-size:12px;color:var(--text-muted);margin-top:2px}

  /* HI-YIELD */
  .hiyield{background:linear-gradient(135deg,rgba(244,114,182,.08),rgba(244,114,182,.02));border:1px solid rgba(244,114,182,.25);border-left:3px solid var(--accent);border-radius:10px;padding:20px 24px;margin-bottom:48px}
  .hiyield-header{display:flex;align-items:center;gap:8px;font-family:'DM Mono',monospace;font-size:11px;text-transform:uppercase;letter-spacing:.12em;color:var(--accent);margin-bottom:14px}
  .hiyield ul{list-style:none;display:grid;grid-template-columns:repeat(auto-fill,minmax(290px,1fr));gap:8px}
  .hiyield ul li{font-size:13px;color:var(--text);padding-left:16px;position:relative;line-height:1.5}
  .hiyield ul li::before{content:'â–¸';position:absolute;left:0;color:var(--accent);font-size:11px}

  strong.hl {color:var(--accent);font-weight:600}
  strong.hl2{color:var(--accent2);font-weight:600}
  strong.hl3{color:var(--accent3);font-weight:600}
  strong.hl4{color:var(--accent4);font-weight:600}
  strong.hlp{color:var(--purple);font-weight:600}
  strong.hld{color:var(--danger);font-weight:600}
  strong.hls{color:var(--sky);font-weight:600}

  /* TABLE */
  .t{width:100%;border-collapse:collapse;font-size:13px;margin:10px 0}
  .t th{background:var(--surface2);color:var(--accent);font-family:'DM Mono',monospace;font-size:10px;text-transform:uppercase;letter-spacing:.08em;padding:8px 12px;text-align:left;border-bottom:1px solid var(--border)}
  .t td{padding:7px 12px;border-bottom:1px solid var(--border);color:var(--text);vertical-align:top;line-height:1.55}
  .t tr:hover td{background:rgba(255,255,255,.02)}
  .t .lbl{font-family:'DM Mono',monospace;font-size:11px;color:var(--accent4);white-space:nowrap;font-weight:500}
  .t .lbl2{font-family:'DM Mono',monospace;font-size:11px;color:var(--accent2);white-space:nowrap;font-weight:500}
  .t .lbl3{font-family:'DM Mono',monospace;font-size:11px;color:var(--accent);white-space:nowrap;font-weight:500}

  /* SUB-HEADER inside card */
  .sub-hdr{margin-top:18px;font-family:'DM Mono',monospace;font-size:11px;text-transform:uppercase;letter-spacing:.1em;color:var(--accent2)}

  /* SECTION LABEL */
  .section-label{font-family:'DM Mono',monospace;font-size:11px;text-transform:uppercase;letter-spacing:.14em;color:var(--text-muted);margin-bottom:16px;display:flex;align-items:center;gap:10px}
  .section-label::after{content:'';flex:1;height:1px;background:var(--border)}

  /* CARDS */
  .chapters-grid{display:flex;flex-direction:column;gap:12px;margin-bottom:48px}
  .chapter-card{background:var(--surface);border:1px solid var(--border);border-radius:12px;overflow:hidden;transition:border-color .2s,box-shadow .2s}
  .chapter-card:hover{border-color:rgba(244,114,182,.35);box-shadow:0 4px 20px rgba(0,0,0,.3)}
  .chapter-header{display:flex;align-items:center;gap:14px;padding:16px 20px;cursor:pointer;user-select:none}
  .ch-num{font-family:'DM Mono',monospace;font-size:11px;font-weight:500;color:var(--text-muted);background:var(--surface2);border:1px solid var(--border);border-radius:6px;padding:3px 8px;white-space:nowrap;min-width:48px;text-align:center}
  .ch-title{flex:1;font-size:15px;font-weight:500;color:var(--text)}
  .ch-tags{display:flex;gap:6px;flex-wrap:wrap}
  .tag{font-family:'DM Mono',monospace;font-size:9px;text-transform:uppercase;letter-spacing:.08em;padding:2px 7px;border-radius:4px;border:1px solid}
  .tag-hiy {color:var(--accent4);border-color:rgba(251,191,36,.3);background:rgba(251,191,36,.08)}
  .tag-crit{color:var(--danger);border-color:rgba(248,113,113,.3);background:rgba(248,113,113,.08)}
  .tag-auto{color:var(--accent);border-color:rgba(244,114,182,.3);background:rgba(244,114,182,.08)}
  .tag-rx  {color:var(--accent3);border-color:rgba(52,211,153,.3);background:rgba(52,211,153,.08)}
  .tag-vasc{color:var(--purple);border-color:rgba(167,139,250,.3);background:rgba(167,139,250,.08)}
  .tag-inf {color:var(--sky);border-color:rgba(96,165,250,.3);background:rgba(96,165,250,.08)}
  .ch-toggle{color:var(--text-muted);font-size:18px;transition:transform .3s;line-height:1}
  .chapter-card.open .ch-toggle{transform:rotate(180deg)}
  .chapter-body{display:none;padding:0 20px 20px;border-top:1px solid var(--border);animation:slideIn .2s ease}
  @keyframes slideIn{from{opacity:0;transform:translateY(-6px)}to{opacity:1;transform:translateY(0)}}
  .chapter-card.open .chapter-body{display:block}

  .key-points{list-style:none;display:flex;flex-direction:column;gap:6px;margin-top:10px}
  .key-points li{font-size:13.5px;color:var(--text);padding:8px 12px;background:var(--surface2);border-radius:6px;border-left:2px solid var(--border);line-height:1.6}
  .key-points li.imp {border-left-color:var(--accent4)}
  .key-points li.crit{border-left-color:var(--danger)}
  .key-points li.note{border-left-color:var(--sky)}
  .key-points li.grn {border-left-color:var(--accent3)}
  .key-points li.pur {border-left-color:var(--purple)}
  .key-points li.pnk{border-left-color:var(--accent)}

  .mnemonic{margin-top:12px;background:rgba(244,114,182,.07);border:1px dashed rgba(244,114,182,.25);border-radius:8px;padding:10px 14px;font-size:13px;color:var(--accent)}
  .mnemonic::before{content:'ðŸ’¡ '}

  /* PROGRESS */
  .progress-wrap{margin-bottom:32px}
  .progress-label{font-family:'DM Mono',monospace;font-size:11px;color:var(--text-muted);margin-bottom:6px;display:flex;justify-content:space-between}
  .progress-bar{height:4px;background:var(--border);border-radius:2px;overflow:hidden}
  .progress-fill{height:100%;background:linear-gradient(90deg,var(--accent),var(--purple));border-radius:2px;width:0%;transition:width .4s ease}

  .footer{margin-top:60px;padding-top:24px;border-top:1px solid var(--border);display:flex;justify-content:space-between;flex-wrap:wrap;gap:8px;font-family:'DM Mono',monospace;font-size:11px;color:var(--text-dim)}
  .chapter-card.hidden{display:none}

  @media(max-width:600px){
    .hero::after{font-size:80px}
    .stats-strip{grid-template-columns:repeat(2,1fr)}
    .hiyield ul{grid-template-columns:1fr}
    .ch-tags{display:none}
    .t{font-size:12px}
  }
</style>
</head>
<body>

<div class="search-bar">
  <div class="search-inner">
    <input class="search-input" type="text" id="searchInput" placeholder="Search JIA, lupus, Kawasaki, vasculitis, dermatomyositisâ€¦" oninput="filterChapters()">
    <span class="chapter-count" id="chapterCount">20 chapters</span>
  </div>
</div>

<div class="pw">

  <!-- HERO -->
  <div class="hero">
    <div class="hero-tag">Nelson Textbook of Pediatrics Â· 22nd Edition Â· 2024</div>
    <h1>Part <span>XIV</span><br>Rheumatic Diseases<br>of Childhood</h1>
    <p class="hero-sub">Exam-oriented study notes covering Chapters 194â€“213. JIA, SLE, Kawasaki disease, vasculitis, dermatomyositis, scleroderma, autoinflammatory syndromes, and more.</p>
    <div class="hero-meta">
      <div class="meta-pill"><span class="dot" style="background:var(--accent)"></span> 20 Chapters</div>
      <div class="meta-pill"><span class="dot" style="background:var(--accent2)"></span> Autoantibody Tables</div>
      <div class="meta-pill"><span class="dot" style="background:var(--purple)"></span> Vasculitis Classification</div>
      <div class="meta-pill"><span class="dot" style="background:var(--danger)"></span> Diagnostic Criteria</div>
    </div>
  </div>

  <!-- PROGRESS -->
  <div class="progress-wrap">
    <div class="progress-label">
      <span>Reading Progress</span>
      <span id="progressText">0 / 20 opened</span>
    </div>
    <div class="progress-bar"><div class="progress-fill" id="progressFill"></div></div>
  </div>

  <!-- STATS -->
  <div class="stats-strip">
    <div class="stat-card">
      <div class="stat-label">Most common arthritis in kids</div>
      <div class="stat-value">JIA</div>
      <div class="stat-desc">Juvenile Idiopathic Arthritis; 6 subtypes; most common = oligoarticular</div>
    </div>
    <div class="stat-card">
      <div class="stat-label">Kawasaki fever duration</div>
      <div class="stat-value">â‰¥5 days</div>
      <div class="stat-desc">Plus â‰¥4 of 5 criteria; treat with IVIG + aspirin</div>
    </div>
    <div class="stat-card">
      <div class="stat-label">Lupus diagnostic criteria</div>
      <div class="stat-value">SLICC / ACR</div>
      <div class="stat-desc">â‰¥4 of 11 ACR criteria; ANA positive in &gt;95% of SLE</div>
    </div>
    <div class="stat-card">
      <div class="stat-label">Most specific SLE antibody</div>
      <div class="stat-value">Anti-dsDNA</div>
      <div class="stat-desc">Also anti-Sm; ANA sensitive but not specific</div>
    </div>
  </div>

  <!-- HIGH YIELD -->
  <div class="hiyield">
    <div class="hiyield-header">âš¡ High-Yield Exam Points â€” Part XIV</div>
    <ul>
      <li><strong class="hl">JIA</strong>: arthritis &gt;6 weeks, &lt;16 years old, no other cause; oligoarticular most common (4 joints); uveitis #1 complication</li>
      <li><strong class="hld">Oligoarticular JIA</strong>: ANA+ â†’ high uveitis risk â†’ screen every 3â€“4 months with slit-lamp</li>
      <li><strong class="hld">Systemic JIA (sJIA)</strong>: quotidian salmon-pink rash + fever spikes + arthritis; risk of MAS (macrophage activation syndrome)</li>
      <li><strong class="hl">SLE</strong>: malar rash (spares nasolabial folds), discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal disease, neuropsych, hematologic, ANA</li>
      <li><strong class="hlp">Anti-dsDNA</strong>: most specific for SLE + correlates with disease activity/lupus nephritis</li>
      <li><strong class="hl2">Kawasaki disease</strong>: fever â‰¥5 days + 4/5 criteria; IVIG 2 g/kg single dose + aspirin; coronary artery aneurysm = #1 complication</li>
      <li><strong class="hld">Kawasaki incomplete</strong>: &lt;4 criteria but suspicious â†’ echo + labs (CRP, ESR, albumin, ALT, platelets, WBC); treat if coronary changes</li>
      <li><strong class="hl">IgA vasculitis (HSP)</strong>: palpable purpura (non-thrombocytopenic) on buttocks/legs + arthritis + abdominal pain + renal disease; IgA deposits</li>
      <li><strong class="hl2">Juvenile dermatomyositis</strong>: Gottron papules + heliotrope rash + proximal muscle weakness + â†‘CPK/aldolase; no malignancy association in children (unlike adults)</li>
      <li><strong class="hl3">MAS (Macrophage Activation Syndrome)</strong>: life-threatening complication of sJIA; â†‘ferritin (&gt;500, often &gt;10,000) + cytopenias + â†‘LFTs + fibrinogen drops; treat with high-dose steroids Â± cyclosporine</li>
      <li><strong class="hlp">Reactive arthritis</strong>: triad = urethritis + conjunctivitis + arthritis; post-infectious (Chlamydia, Salmonella, Shigella, Yersinia, Campylobacter)</li>
      <li><strong class="hls">FMF (Familial Mediterranean Fever)</strong>: MEFV gene; recurrent fever + serositis + arthritis; treat with colchicine</li>
      <li><strong class="hl4">ANCA-associated vasculitis</strong>: GPA (formerly Wegener) = c-ANCA/PR3; MPA = p-ANCA/MPO; treat with steroids + cyclophosphamide or rituximab</li>
    </ul>
  </div>

  <!-- CHAPTERS -->
  <div class="section-label">Chapters 194 â€“ 213</div>
  <div class="chapters-grid" id="chaptersGrid">

    <!-- CH 194 -->
    <div class="chapter-card" data-keywords="evaluation suspected rheumatic disease history examination ANA ESR CRP RF laboratory arthritis approach">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 194</span>
        <span class="ch-title">Evaluation of Suspected Rheumatic Disease</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Approach: duration of symptoms (arthritis must be &gt;6 weeks for JIA), pattern (oligoarticular vs polyarticular), morning stiffness, systemic features (fever, rash, weight loss)</li>
          <li class="imp">Key lab workup: CBC, ESR, CRP, ANA, RF, anti-CCP, complement (C3, C4, CH50), urinalysis, LFTs, CK</li>
        </ul>
        <div class="sub-hdr">â–¸ Autoantibody Quick Reference</div>
        <table class="t">
          <thead><tr><th>Antibody</th><th>Associated Disease</th><th>Notes</th></tr></thead>
          <tbody>
            <tr><td class="lbl">ANA</td><td>SLE, scleroderma, JIA (oligo), SjÃ¶gren, dermatomyositis, drug-induced lupus</td><td>Sensitive but NOT specific; positive in 5â€“15% of healthy people</td></tr>
            <tr><td class="lbl">Anti-dsDNA</td><td><strong class="hld">SLE (most specific)</strong></td><td>Correlates with disease activity &amp; lupus nephritis; â†‘during flare</td></tr>
            <tr><td class="lbl">Anti-Sm</td><td>SLE</td><td>Highly specific for SLE (~25% sensitive)</td></tr>
            <tr><td class="lbl">Anti-Ro (SS-A)</td><td>SLE, SjÃ¶gren, neonatal lupus</td><td>Neonatal lupus â†’ congenital heart block; photosensitivity</td></tr>
            <tr><td class="lbl">Anti-La (SS-B)</td><td>SjÃ¶gren, neonatal lupus</td><td>Usually seen with anti-Ro</td></tr>
            <tr><td class="lbl">Anti-Scl-70 (anti-topoisomerase I)</td><td>Diffuse systemic sclerosis</td><td>Pulmonary fibrosis risk</td></tr>
            <tr><td class="lbl">Anti-centromere</td><td>Limited scleroderma (CREST)</td><td>Better prognosis; PAH risk</td></tr>
            <tr><td class="lbl">Anti-Jo-1</td><td>Polymyositis / dermatomyositis</td><td>Anti-synthetase syndrome: myositis + ILD + mechanic's hands</td></tr>
            <tr><td class="lbl">RF (Rheumatoid Factor)</td><td>Polyarticular JIA (RF+), RA</td><td>IgM anti-IgG; poor specificity</td></tr>
            <tr><td class="lbl">Anti-CCP</td><td>RF+ JIA, RA</td><td>More specific than RF; predicts erosive disease</td></tr>
            <tr><td class="lbl">c-ANCA (PR3)</td><td>Granulomatosis with polyangiitis (GPA)</td><td>Upper + lower airway + renal involvement</td></tr>
            <tr><td class="lbl">p-ANCA (MPO)</td><td>MPA, eosinophilic GPA, IBD</td><td>More renal involvement</td></tr>
            <tr><td class="lbl">Antiphospholipid Ab (anti-cardiolipin, lupus anticoagulant, anti-Î²2GPI)</td><td>Antiphospholipid syndrome (APS), SLE</td><td>Thrombosis + recurrent pregnancy loss; paradoxically â†‘PTT but pro-thrombotic</td></tr>
          </tbody>
        </table>
        <div class="mnemonic">ANA = sensitive (screens) | anti-dsDNA = specific + active disease | anti-Sm = specific | anti-Ro = neonatal lupus risk</div>
      </div>
    </div>

    <!-- CH 195 -->
    <div class="chapter-card" data-keywords="treatment rheumatic diseases NSAIDs DMARDs methotrexate hydroxychloroquine biologics TNF inhibitors steroids corticosteroids JAK inhibitors">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 195</span>
        <span class="ch-title">Treatment of Rheumatic Diseases</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-rx">Drugs</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <table class="t">
          <thead><tr><th>Drug Class</th><th>Examples</th><th>Mechanism</th><th>Key Side Effects / Notes</th></tr></thead>
          <tbody>
            <tr><td class="lbl">NSAIDs</td><td>Naproxen, ibuprofen, indomethacin, meloxicam</td><td>COX-1/2 inhibition â†’ â†“prostaglandins</td><td>GI ulceration, renal impairment, pseudoporphyria (naproxen); first-line for mild JIA</td></tr>
            <tr><td class="lbl">Corticosteroids</td><td>Prednisone, methylprednisolone</td><td>Broad anti-inflammatory + immunosuppressive</td><td>Cushing, osteoporosis, growth suppression, hyperglycemia, cataracts, avascular necrosis, infection risk; use lowest dose shortest time</td></tr>
            <tr><td class="lbl">Methotrexate (MTX)</td><td>â€”</td><td>Folate antagonist â†’ â†“inflammation; DMARD</td><td><strong class="hld">Hepatotoxicity</strong>, mucositis, myelosuppression, teratogen (folic acid supplement with use); monitor LFTs; first-line DMARD for JIA</td></tr>
            <tr><td class="lbl">Hydroxychloroquine (HCQ)</td><td>Plaquenil</td><td>Lysosomal alkalinization â†’ â†“antigen presentation</td><td><strong class="hld">Retinal toxicity</strong> (baseline eye exam, annual screening); safe in pregnancy; used in SLE, SjÃ¶gren</td></tr>
            <tr><td class="lbl">Sulfasalazine</td><td>â€”</td><td>DMARD; anti-inflammatory</td><td>GI side effects, sulfa allergy; used in SpA/enthesitis-related arthritis</td></tr>
            <tr><td class="lbl">TNF-Î± Inhibitors</td><td>Etanercept, adalimumab, infliximab</td><td>Block TNF-Î±</td><td><strong class="hld">TB reactivation</strong> â€” screen with TST/IGRA before starting; infection risk; demyelination (avoid in MS); etanercept most used in JIA</td></tr>
            <tr><td class="lbl">IL-1 Inhibitors</td><td>Anakinra, canakinumab</td><td>Block IL-1Î²</td><td>Used for systemic JIA, FMF, CAPS; injection site reactions</td></tr>
            <tr><td class="lbl">IL-6 Inhibitors</td><td>Tocilizumab</td><td>Block IL-6 receptor</td><td>Systemic JIA, polyarticular JIA; â†‘LFTs, neutropenia, infection; masks fever (diagnostic challenge)</td></tr>
            <tr><td class="lbl">Abatacept</td><td>â€”</td><td>CTLA-4-Ig; blocks T-cell co-stimulation (CD80/86â€“CD28)</td><td>Used in RF+ polyarticular JIA</td></tr>
            <tr><td class="lbl">Rituximab</td><td>â€”</td><td>Anti-CD20 â†’ B-cell depletion</td><td>Used in SLE, vasculitis (GPA), refractory JIA; PML risk (rare)</td></tr>
            <tr><td class="lbl">Mycophenolate mofetil (MMF)</td><td>CellCept</td><td>Inhibits purine synthesis â†’ â†“lymphocyte proliferation</td><td>Lupus nephritis; teratogen; GI side effects</td></tr>
            <tr><td class="lbl">Cyclophosphamide</td><td>â€”</td><td>Alkylating agent â†’ cytotoxic</td><td>Hemorrhagic cystitis (give mesna), gonadotoxicity, malignancy; severe lupus nephritis, GPA</td></tr>
            <tr><td class="lbl">Colchicine</td><td>â€”</td><td>Inhibits microtubule polymerization â†’ â†“neutrophil migration</td><td>FMF, gout, pericarditis; diarrhea; safe in pregnancy at standard doses</td></tr>
            <tr><td class="lbl">JAK inhibitors</td><td>Tofacitinib, baricitinib, upadacitinib</td><td>Inhibit JAK-STAT signaling</td><td>Oral; infection risk (VZV reactivation â€” check varicella immunity); â†‘lipids, thrombosis; used in polyarticular JIA</td></tr>
          </tbody>
        </table>
        <div class="mnemonic">TNF-i: screen for TB first! | MTX: folate supplement, watch LFTs | HCQ: eye exams | Cyclophosphamide: mesna for bladder</div>
      </div>
    </div>

    <!-- CH 196 -->
    <div class="chapter-card" data-keywords="juvenile idiopathic arthritis JIA oligoarticular polyarticular systemic enthesitis psoriatic uveitis ANA RF methotrexate etanercept">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 196</span>
        <span class="ch-title">Juvenile Idiopathic Arthritis (JIA)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Definition: arthritis (swelling OR 2 of: pain, limited motion, tenderness, warmth) in â‰¥1 joint for &gt;6 weeks, onset &lt;16 years, no other cause identifiable</li>
          <li class="crit"><strong class="hld">Uveitis (iridocyclitis)</strong>: most common extra-articular complication; anterior, non-granulomatous, typically ASYMPTOMATIC â€” must screen with slit-lamp examination; risk highest in ANA+ oligoarticular JIA in young girls</li>
        </ul>
        <table class="t">
          <thead><tr><th>Subtype</th><th>% of JIA</th><th>Joints</th><th>Labs</th><th>Uveitis Risk</th><th>Prognosis / Notes</th></tr></thead>
          <tbody>
            <tr>
              <td class="lbl">Oligoarticular<br>(persistent)</td>
              <td>~50%</td>
              <td>â‰¤4 joints in first 6 mo; large joints (knee, ankle); asymmetric</td>
              <td>ANA+ (~75%); RFâ€“; ESR variable</td>
              <td><strong class="hld">HIGHEST â€” 20â€“30%</strong>; silent; must screen</td>
              <td>Best prognosis; 50% remit; leg length discrepancy if knee involved</td>
            </tr>
            <tr>
              <td class="lbl">Oligoarticular<br>(extended)</td>
              <td>â€”</td>
              <td>â‰¤4 joints first 6 mo â†’ &gt;4 joints after 6 mo</td>
              <td>ANA+ variable</td>
              <td>High</td>
              <td>Worse prognosis than persistent; treat like polyarticular</td>
            </tr>
            <tr>
              <td class="lbl">Polyarticular<br>RFâ€“</td>
              <td>~20%</td>
              <td>â‰¥5 joints; large + small; symmetric</td>
              <td>ANA+ variable; RFâ€“</td>
              <td>Moderate (15%)</td>
              <td>Variable; MTX first-line DMARD</td>
            </tr>
            <tr>
              <td class="lbl">Polyarticular<br>RF+</td>
              <td>~5%</td>
              <td>â‰¥5 joints; symmetric; small joints of hands/feet; adolescent girls</td>
              <td><strong class="hl">RF+, anti-CCP+</strong></td>
              <td>Low</td>
              <td>Worst articular prognosis; erosive disease; resembles adult RA; aggressive DMARD therapy</td>
            </tr>
            <tr>
              <td class="lbl">Systemic JIA<br>(sJIA / Still's)</td>
              <td>~10%</td>
              <td>Any number of joints; arthritis may lag behind systemic features</td>
              <td>â†‘â†‘ferritin, â†‘WBC, â†‘CRP; RFâ€“; ANAâ€“</td>
              <td>Rare</td>
              <td><strong class="hld">Quotidian fever</strong> (spikes once or twice daily, returns to normal); <strong class="hld">salmon-pink evanescent rash</strong> (appears with fever); serositis (pericarditis, pleuritis); risk of MAS (most feared)</td>
            </tr>
            <tr>
              <td class="lbl">Enthesitis-related<br>arthritis (ERA)</td>
              <td>~10%</td>
              <td>Peripheral arthritis + enthesitis (insertion points); sacroiliac joints; lower extremity predominance</td>
              <td><strong class="hl">HLA-B27+</strong> (~90%); RFâ€“; ANAâ€“</td>
              <td>Acute anterior uveitis (symptomatic, unilateral, red eye â€” unlike other JIA)</td>
              <td>Adolescent males; will develop ankylosing spondylitis in many; use NSAIDs + TNF-i</td>
            </tr>
            <tr>
              <td class="lbl">Psoriatic JIA</td>
              <td>~5%</td>
              <td>Oligoarticular; DIP involvement; asymmetric; dactylitis ("sausage digits")</td>
              <td>ANA variable; RFâ€“</td>
              <td>Moderate</td>
              <td>Psoriasis rash (may come after arthritis); nail pitting; family history of psoriasis counts</td>
            </tr>
          </tbody>
        </table>
        <div class="sub-hdr">â–¸ Uveitis Screening Frequency (ACR Guidelines)</div>
        <ul class="key-points">
          <li class="crit">Highest risk (every 3 months): oligoarticular OR polyarticular JIA + ANA+ + age &lt;7 at onset + disease duration &lt;4 yrs</li>
          <li class="imp">Lower risk: ANAâ€“ or older onset â†’ every 6â€“12 months</li>
          <li class="crit">ERA uveitis is SYMPTOMATIC (red, painful eye) â€” unlike oligoarticular (silent)</li>
        </ul>
        <div class="sub-hdr">â–¸ MAS (Macrophage Activation Syndrome)</div>
        <ul class="key-points">
          <li class="crit">Life-threatening complication of sJIA (also SLE, infections); hemophagocytic lymphohistiocytosis (HLH) spectrum</li>
          <li class="crit">Features: persistent high fever, â†“â†“WBC + â†“PLT + â†“Hgb (pancytopenia), <strong class="hld">â†‘â†‘ferritin (&gt;500 ng/mL, often &gt;10,000)</strong>, â†‘LFTs, â†‘D-dimer, â†“fibrinogen, hepatosplenomegaly, encephalopathy</li>
          <li class="crit">Paradox: ESR falls (fibrinogen consumed); CRP remains high</li>
          <li class="imp">Treatment: high-dose IV steroids (methylprednisolone) Â± cyclosporine Â± anakinra (IL-1 blockade); etoposide in refractory</li>
        </ul>
        <div class="mnemonic">sJIA = Salmon rash + Spiky fever + Serositis + Still's + MAS risk | Oligo JIA = ANA+ â†’ Silent uveitis â†’ Slit-lamp screening</div>
      </div>
    </div>

    <!-- CH 197 -->
    <div class="chapter-card" data-keywords="ankylosing spondylitis spondyloarthritis HLA-B27 sacroiliitis enthesitis inflammatory back pain IBD arthritis uveitis psoriasis">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 197</span>
        <span class="ch-title">Ankylosing Spondylitis and Other Spondyloarthritides</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Spondyloarthropathies (SpA)</strong>: group of inflammatory disorders sharing HLA-B27 association, sacroiliitis, enthesitis, and extra-articular features</li>
          <li class="imp">Includes: Ankylosing spondylitis (AS), Psoriatic arthritis, IBD-associated arthritis, Reactive arthritis, Undifferentiated SpA</li>
          <li class="imp"><strong class="hl">HLA-B27</strong>: present in ~90% of AS patients; 5â€“10% of HLA-B27+ individuals develop AS; NOT a diagnostic test alone</li>
          <li class="imp">AS clinical features: insidious inflammatory low back pain (worse with rest, better with activity; morning stiffness &gt;30 min), sacroiliitis, progressive spinal fusion ("bamboo spine" on X-ray), chest wall restriction (â†“chest expansion)</li>
          <li class="imp">Extra-articular: <strong class="hld">anterior uveitis</strong> (acute, painful, unilateral, recurrent), aortic regurgitation, apical lung fibrosis, IgA nephropathy</li>
          <li class="imp">X-ray: squaring of vertebral bodies â†’ syndesmophytes â†’ bamboo spine. Sacroiliac joint sclerosis/fusion. MRI more sensitive in early disease</li>
          <li class="note">Treatment: NSAIDs first-line; physiotherapy essential; <strong class="hl3">TNF-Î± inhibitors</strong> (etanercept, adalimumab) if NSAID-refractory; IL-17 inhibitors (secukinumab) alternative; no role for conventional DMARDs (MTX) for axial disease</li>
        </ul>
        <div class="mnemonic">SpA: "PAIR" â†’ Psoriasis, Ankylosing spondylitis, IBD arthritis, Reactive arthritis; all HLA-B27 associated</div>
      </div>
    </div>

    <!-- CH 198 -->
    <div class="chapter-card" data-keywords="reactive arthritis postinfectious Reiter syndrome urethritis conjunctivitis Chlamydia Salmonella Shigella Yersinia Campylobacter streptococcal">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 198</span>
        <span class="ch-title">Reactive and Postinfectious Arthritis</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-inf">Infection</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Reactive arthritis</strong>: sterile inflammatory arthritis triggered by a remote infection (1â€“4 weeks prior); joints NOT infected</li>
          <li class="imp">Classic triad (Reiter syndrome): <strong class="hl2">Urethritis + Conjunctivitis + Arthritis</strong> ("Can't see, can't pee, can't climb a tree"); not all 3 required for diagnosis</li>
          <li class="imp">Causative organisms: <strong class="hl4">Chlamydia trachomatis</strong> (STI-associated, adolescents), <strong class="hl4">Salmonella, Shigella, Yersinia, Campylobacter</strong> (enteric), group A Streptococcus (post-strep arthritis)</li>
          <li class="note">HLA-B27+ â†’ more severe and prolonged course; asymmetric oligoarthritis; large joints of lower extremity</li>
          <li class="note">Other features: keratoderma blennorrhagica (psoriasis-like skin lesions), circinate balanitis, painless oral ulcers, dactylitis, plantar fasciitis, Achilles tendinitis</li>
          <li class="imp">Post-streptococcal arthritis: occurs after GAS pharyngitis; does NOT fully meet Jones criteria for rheumatic fever; may not respond to aspirin; treat GAS</li>
          <li class="note">Treatment: NSAIDs for arthritis; antibiotics for active infection (Chlamydia); course usually self-limited (3â€“6 months); some develop chronic SpA</li>
        </ul>
        <div class="mnemonic">Reactive arthritis organisms: "Can't SSYCt" â†’ Chlamydia, Salmonella, Shigella, Yersinia, Campylobacter</div>
      </div>
    </div>

    <!-- CH 199 -->
    <div class="chapter-card" data-keywords="systemic lupus erythematosus SLE malar rash butterfly discoid photosensitivity oral ulcer arthritis serositis renal nephritis ANA anti-dsDNA anti-Sm complement neonatal lupus drug-induced">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 199</span>
        <span class="ch-title">Systemic Lupus Erythematosus (SLE)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Pediatric SLE: peak onset in adolescence; females predominate (9:1 after puberty); African American, Hispanic, Asian populations at higher risk</li>
          <li class="imp">Pediatric SLE more severe than adult: more renal involvement, CNS disease, hematologic abnormalities at presentation</li>
        </ul>
        <div class="sub-hdr">â–¸ ACR/EULAR Diagnostic Criteria (â‰¥4 of 11 ACR, or SLICC â‰¥4 of 17)</div>
        <table class="t">
          <thead><tr><th>Domain</th><th>Feature</th><th>Notes</th></tr></thead>
          <tbody>
            <tr><td class="lbl3">Skin</td><td><strong class="hl">Malar (butterfly) rash</strong> â€” erythema over cheeks and nose, <strong class="hl">spares nasolabial folds</strong>; discoid rash (scarring); photosensitivity; oral ulcers (painless)</td><td>Malar rash in ~50%; photosensitivity; subacute cutaneous lupus</td></tr>
            <tr><td class="lbl3">MSK</td><td>Non-erosive arthritis (â‰¥2 joints); arthralgia</td><td>Jaccoud arthropathy â€” deforming but non-erosive</td></tr>
            <tr><td class="lbl3">Serositis</td><td>Pleuritis, pericarditis</td><td>Chest pain + friction rub; pleural effusion</td></tr>
            <tr><td class="lbl3">Renal</td><td>Proteinuria &gt;500 mg/24h; red cell casts; nephritic/nephrotic syndrome</td><td><strong class="hld">WHO Class III/IV (diffuse proliferative) = worst prognosis</strong>; need biopsy to classify; treat with steroids + MMF or cyclophosphamide</td></tr>
            <tr><td class="lbl3">Neuropsych</td><td>Seizures, psychosis, CNS vasculitis, cognitive impairment, headache, chorea</td><td>"Lupus cerebritis"; chorea in SLE (anti-phospholipid)</td></tr>
            <tr><td class="lbl3">Hematologic</td><td>Hemolytic anemia (Coombs+), leukopenia (&lt;4000), lymphopenia (&lt;1000), thrombocytopenia (&lt;100,000)</td><td>Any one counts; all can be presenting manifestation</td></tr>
            <tr><td class="lbl3">Immunologic</td><td>Anti-dsDNA, anti-Sm, antiphospholipid antibodies, low complement (C3, C4)</td><td>â†‘anti-dsDNA + â†“complement = disease flare marker</td></tr>
            <tr><td class="lbl3">ANA</td><td>ANA positive (â‰¥1:80)</td><td>&gt;95% sensitive; if ANA negative, SLE very unlikely</td></tr>
          </tbody>
        </table>
        <ul class="key-points">
          <li class="crit">Drug-induced lupus: procainamide, hydralazine, isoniazid, minocycline, anti-TNF; anti-histone Ab+ ; NO renal/CNS involvement; resolves with drug discontinuation</li>
          <li class="imp">Neonatal lupus: maternal anti-Ro/La antibodies cross placenta â†’ transient rash, cytopenias, <strong class="hld">congenital complete heart block</strong> (permanent â€” may need pacemaker)</li>
          <li class="imp">Antiphospholipid syndrome in SLE: venous/arterial thrombosis + recurrent pregnancy loss + persistent antiphospholipid antibodies; treat with anticoagulation</li>
        </ul>
        <div class="sub-hdr">â–¸ Treatment</div>
        <ul class="key-points">
          <li class="grn">All SLE patients: <strong class="hl3">hydroxychloroquine</strong> (reduces flares, organ damage, mortality, thrombosis; safe in pregnancy)</li>
          <li class="imp">Mild: NSAIDs + HCQ. Moderate: add low-dose steroids. Severe (nephritis, CNS, hematologic): high-dose steroids + MMF or cyclophosphamide</li>
          <li class="note">Belimumab (anti-BLyS): FDA-approved for pediatric SLE â‰¥5 yrs; reduces flares, lowers steroids</li>
          <li class="note">Sun protection critical (photosensitivity); monitor anti-dsDNA + C3/C4 to track activity</li>
        </ul>
        <div class="mnemonic">SLE = "MD SOAP RAN" â†’ Malar rash, Discoid rash, Serositis, Oral ulcers, Arthritis, Photosensitivity, Renal, ANA, Neurologic, hematologic (Blood)</div>
      </div>
    </div>

    <!-- CH 200 -->
    <div class="chapter-card" data-keywords="juvenile dermatomyositis Gottron papules heliotrope rash proximal muscle weakness CPK aldolase calcinosis interstitial lung anti-Jo-1">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 200</span>
        <span class="ch-title">Juvenile Dermatomyositis (JDM)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Most common idiopathic inflammatory myopathy in children; peak onset 5â€“14 yrs; girls &gt; boys (2:1)</li>
          <li class="crit">Pathognomonic skin features:
            <ul style="margin-top:6px;padding-left:16px">
              <li><strong class="hld">Gottron papules</strong>: scaly, erythematous papules over dorsal MCP and PIP joints ("knuckle pads") â€” most specific finding</li>
              <li><strong class="hld">Heliotrope rash</strong>: violaceous/lilac discoloration of upper eyelids with periorbital edema (heliotrope = purple flower)</li>
            </ul>
          </li>
          <li class="imp">Other skin: V-sign (anterior neck/chest), shawl sign (posterior neck/shoulders), mechanic's hands (fissured palms), periungual telangiectasias, nailfold capillary changes</li>
          <li class="imp">Muscle: <strong class="hl">symmetric proximal muscle weakness</strong> (hip flexors, shoulder girdle); difficulty rising from floor, climbing stairs; Gowers sign; dysphagia (pharyngeal muscles)</li>
          <li class="imp">Labs: <strong class="hl2">â†‘CK, â†‘aldolase, â†‘LDH, â†‘AST/ALT</strong>; anti-Jo-1 (antisynthetase â€” ILD + myositis + mechanic's hands); ANA variable; normal RF</li>
          <li class="crit">Unlike adult dermatomyositis: <strong class="hld">NO increased malignancy risk in children</strong></li>
          <li class="imp">Complications: <strong class="hld">calcinosis</strong> (calcium deposits in skin/muscle â€” most common complication, may be disfiguring); interstitial lung disease (with anti-Jo-1); vasculopathy â†’ GI ulceration/perforation (dangerous)</li>
          <li class="note">Diagnosis: clinical + muscle enzymes + MRI (muscle edema) + EMG + muscle biopsy (perifascicular atrophy â€” pathognomonic on biopsy)</li>
          <li class="imp">Treatment: high-dose steroids (prednisone 1â€“2 mg/kg/day) â†’ taper; MTX or azathioprine as steroid-sparing; IVIG for refractory; HCQ for skin; avoid sun</li>
        </ul>
        <div class="mnemonic">JDM: Gottron papules + Heliotrope + proximal muscle Weakness + â†‘CK = classic triad; NO malignancy risk in kids</div>
      </div>
    </div>

    <!-- CH 201 -->
    <div class="chapter-card" data-keywords="scleroderma systemic sclerosis diffuse limited CREST Raynaud anti-Scl-70 anti-centromere interstitial lung pulmonary hypertension morphea">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 201</span>
        <span class="ch-title">Scleroderma and Raynaud Phenomenon</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Raynaud phenomenon</strong>: episodic vasospasm of digits triggered by cold or stress; color change: <strong class="hl2">white (ischemia) â†’ blue (cyanosis) â†’ red (reperfusion)</strong>; primary (idiopathic, benign) vs secondary (to scleroderma, SLE, other CTD)</li>
          <li class="imp"><strong class="hl">Localized scleroderma (morphea)</strong>: most common form in children; circumscribed plaques or linear bands of dermal fibrosis; no internal organ involvement; "en coup de sabre" (linear morphea on face/scalp)</li>
          <li class="imp"><strong class="hl">Systemic sclerosis (rare in children)</strong>: fibrosis of skin + internal organs; CREST syndrome (limited): Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasias; anti-centromere Ab+</li>
          <li class="imp">Diffuse systemic sclerosis: anti-Scl-70 (anti-topoisomerase I) Ab+; rapid skin thickening; ILD (most common cause of death), renal crisis (hypertension + AKI â€” treat with ACE inhibitor), PAH, cardiac fibrosis</li>
          <li class="note">Treatment: Raynaud â†’ calcium channel blockers (nifedipine), avoid cold; ILD â†’ MMF; PAH â†’ endothelin receptor antagonists, PDE-5 inhibitors; no curative therapy; skin may soften over time in morphea</li>
        </ul>
        <div class="mnemonic">CREST = Calcinosis, Raynaud, Esophageal dysmotility, Sclerodactyly, Telangiectasia = limited scleroderma = anti-centromere Ab</div>
      </div>
    </div>

    <!-- CH 202 -->
    <div class="chapter-card" data-keywords="BehÃ§et disease oral ulcers genital ulcers uveitis pathergy HLA-B51 Turkey Mediterranean silk road">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 202</span>
        <span class="ch-title">BehÃ§et Disease</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">BehÃ§et disease</strong>: systemic vasculitis of unclear etiology; "Silk Road disease" â€” prevalent in Turkey, Middle East, East Asia; HLA-B51 association</li>
          <li class="imp">Diagnostic criteria (International Study Group): <strong class="hld">recurrent oral ulcers â‰¥3Ã—/year</strong> PLUS â‰¥2 of: recurrent genital ulcers, eye lesions (anterior/posterior uveitis, retinal vasculitis), skin lesions (erythema nodosum, pseudofolliculitis, acneiform lesions), positive pathergy test</li>
          <li class="imp"><strong class="hl2">Pathergy test</strong>: positive when a skin prick with a sterile needle results in an erythematous papule/pustule &gt;2 mm at 48 hrs; specific for BehÃ§et (rarely positive elsewhere)</li>
          <li class="note">Other features: arthritis (non-erosive, large joints), GI ulceration, CNS involvement (neuro-BehÃ§et â€” parenchymal or dural sinus thrombosis), vascular (aneurysms, deep vein thrombosis)</li>
          <li class="note">Treatment: colchicine (oral ulcers, skin, arthritis); steroids for eyes; azathioprine, cyclosporine for severe eye/CNS; TNF-i for refractory</li>
        </ul>
        <div class="mnemonic">BehÃ§et: "Oral + Genital + Ocular + Pathergy" = classic triad + test; HLA-B51; Silk Road</div>
      </div>
    </div>

    <!-- CH 203 -->
    <div class="chapter-card" data-keywords="Sjogren syndrome dry eyes dry mouth keratoconjunctivitis sicca xerostomia anti-Ro anti-La parotid">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 203</span>
        <span class="ch-title">SjÃ¶gren Syndrome</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">SjÃ¶gren syndrome</strong>: autoimmune exocrinopathy causing lymphocytic infiltration of exocrine glands â†’ sicca symptoms; rare in children; F &gt; M (9:1)</li>
          <li class="imp">Cardinal features: <strong class="hl2">keratoconjunctivitis sicca</strong> (dry eyes â€” gritty, burning, photophobia; Schirmer's test: filter paper placed under eyelid, &lt;5 mm wetting in 5 min = abnormal) + <strong class="hl2">xerostomia</strong> (dry mouth â€” dental caries, dysphagia, altered taste)</li>
          <li class="imp">Parotid gland enlargement (bilateral); parotitis episodes in children</li>
          <li class="imp">Autoantibodies: <strong class="hl">anti-Ro (SS-A) and anti-La (SS-B)</strong>; ANA+; RF+ (~75%)</li>
          <li class="note">Extraglandular: interstitial nephritis (RTA type 1), peripheral neuropathy, Raynaud, arthritis, vasculitis, lymphoma risk (25Ã— increased â€” most important complication)</li>
          <li class="note">Neonatal: maternal anti-Ro â†’ neonatal lupus â†’ congenital heart block (shared with SLE)</li>
          <li class="note">Treatment: artificial tears/saliva, pilocarpine (stimulates secretion), HCQ, steroids for systemic disease; rituximab for severe</li>
        </ul>
        <div class="mnemonic">SjÃ¶gren: anti-Ro + anti-La + Sicca symptoms (dry eyes + dry mouth) â†’ lymphoma risk (important!)</div>
      </div>
    </div>

    <!-- CH 204 -->
    <div class="chapter-card" data-keywords="hereditary periodic fever FMF familial Mediterranean fever TRAPS HIDS CAPS PFAPA MEFV pyrin colchicine autoinflammatory">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 204</span>
        <span class="ch-title">Hereditary Periodic Fever Syndromes and Autoinflammatory Diseases</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Autoinflammatory diseases</strong>: innate immune system dysregulation â†’ recurrent inflammation WITHOUT autoantibodies or antigen-specific T cells (distinct from autoimmune diseases)</li>
        </ul>
        <table class="t">
          <thead><tr><th>Disease</th><th>Gene / Protein</th><th>Fever Duration</th><th>Key Features</th><th>Treatment</th></tr></thead>
          <tbody>
            <tr>
              <td class="lbl">FMF (Familial Mediterranean Fever)</td>
              <td><strong class="hl">MEFV / Pyrin</strong>; AR</td>
              <td>1â€“3 days</td>
              <td>Recurrent fever + serositis (peritonitis, pleuritis, pericarditis) + arthritis + erysipelas-like rash on legs; Mediterranean (Turkish, Jewish, Arab, Armenian); amyloidosis risk (AA amyloid â†’ renal failure)</td>
              <td><strong class="hl3">Colchicine</strong> (prevents attacks + prevents amyloidosis); IL-1 inhibitors if colchicine fails</td>
            </tr>
            <tr>
              <td class="lbl">TRAPS (TNF Receptor-Associated Periodic Syndrome)</td>
              <td>TNFRSF1A / TNFR1; AD</td>
              <td>Weeks to months</td>
              <td>Longer fever episodes; migratory myalgia with overlying skin erythema; periorbital edema; serositis; Northern European; amyloidosis risk</td>
              <td>NSAIDs; etanercept (TNF-i); IL-1 inhibitors (canakinumab)</td>
            </tr>
            <tr>
              <td class="lbl">HIDS (Hyper-IgD Syndrome / MKD)</td>
              <td>MVK / Mevalonate kinase; AR</td>
              <td>3â€“7 days; every 4â€“8 wks</td>
              <td>â†‘â†‘IgD (&gt;100 U/mL), â†‘IgA; cervical lymphadenopathy; abdominal pain/vomiting/diarrhea; Dutch origin; aphthous ulcers, arthralgia</td>
              <td>NSAIDs; IL-1 inhibitors; simvastatin (mevalonate pathway)</td>
            </tr>
            <tr>
              <td class="lbl">CAPS (Cryopyrin-Associated Periodic Syndrome)</td>
              <td>NLRP3 / Cryopyrin; AD</td>
              <td>Variable (urticaria-like rash)</td>
              <td>Spectrum: FCAS (cold-induced urticaria) â†’ MWS (deafness, amyloidosis) â†’ NOMID (neonatal onset, chronic meningitis, bone overgrowth, most severe)</td>
              <td><strong class="hl3">IL-1 inhibitors</strong> (anakinra, rilonacept, canakinumab) â€” highly effective</td>
            </tr>
            <tr>
              <td class="lbl">PFAPA (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis)</td>
              <td>Unknown; most common PFS in children</td>
              <td>3â€“6 days; every 3â€“8 wks</td>
              <td>Regular predictable cycles; aphthous ulcers, pharyngitis, cervical adenitis; no genetic test; resolves spontaneously by adolescence; normal growth</td>
              <td>Single dose of prednisone aborts attack (diagnostic); colchicine for prevention; tonsillectomy effective</td>
            </tr>
          </tbody>
        </table>
        <div class="mnemonic">FMF: MEFV gene â†’ Febrile episodes + peritonitis + arthritis + erysipelas; treat with Colchicine â†’ prevents Amyloidosis</div>
      </div>
    </div>

    <!-- CH 205 -->
    <div class="chapter-card" data-keywords="interferonopathies Aicardi-Goutieres type 1 interferonopathy STING AGS JAK inhibitor lupus-like">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 205</span>
        <span class="ch-title">Interferonopathies</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Interferonopathies</strong>: monogenic disorders characterized by constitutive type I interferon (IFN-Î±/Î²) production, leading to systemic inflammation resembling viral infection or SLE</li>
          <li class="imp"><strong class="hl2">Aicardi-GoutiÃ¨res syndrome (AGS)</strong>: most common; recessive mutations in TREX1, RNASEH2, SAMHD1, ADAR, IFIH1; presents in infancy with calcifications (basal ganglia, white matter), progressive encephalopathy, CSF lymphocytosis, chilblain-like skin lesions; mimics congenital infection</li>
          <li class="note"><strong class="hl">STING-associated vasculopathy with onset in infancy (SAVI)</strong>: gain-of-function TMEM173 mutation; interstitial lung disease + cutaneous vasculopathy (chilblains, nasal septum perforation) + systemic inflammation from birth</li>
          <li class="note">Treatment: JAK inhibitors (baricitinib, ruxolitinib) block IFN signaling â†’ symptom improvement; investigational</li>
          <li class="grn">Measurement: elevated IFN signature score (ISG â€” IFN-stimulated gene expression) in blood is a biomarker for diagnosis</li>
        </ul>
      </div>
    </div>

    <!-- CH 206 -->
    <div class="chapter-card" data-keywords="amyloidosis AA amyloid SAA serum amyloid kidney nephrotic FMF JIA secondary">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 206</span>
        <span class="ch-title">Amyloidosis</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">AA amyloidosis</strong>: most common type in pediatric rheumatology; deposition of serum amyloid A (SAA) protein in organs during chronic inflammation</li>
          <li class="imp">Causes: FMF (most common), TRAPS, JIA, Crohn disease, chronic osteomyelitis, tuberculosis</li>
          <li class="imp">Main target organ: <strong class="hld">kidneys</strong> â†’ nephrotic syndrome â†’ renal failure; also liver, spleen, adrenal glands</li>
          <li class="note">Diagnosis: Congo red stain on biopsy â†’ apple-green birefringence under polarized light (classic); rectal or abdominal fat pad biopsy preferred over kidney</li>
          <li class="note">Treatment: colchicine (FMF â€” prevents amyloid); control underlying inflammation; anakinra/canakinumab (sJIA); ESRD â†’ dialysis/transplant</li>
        </ul>
      </div>
    </div>

    <!-- CH 207 -->
    <div class="chapter-card" data-keywords="macrophage activation syndrome MAS HLH hemophagocytic lymphohistiocytosis ferritin sJIA SLE cytokine storm">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 207</span>
        <span class="ch-title">Macrophage Activation Syndrome (MAS) / Secondary HLH</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit">MAS = secondary HLH; life-threatening uncontrolled macrophage and T-cell activation with hyperinflammation ("cytokine storm")</li>
          <li class="crit">Most common triggers in pediatric rheumatology: <strong class="hld">systemic JIA (sJIA)</strong>, SLE, Kawasaki disease, infections (EBV most common infectious trigger)</li>
          <li class="crit">Diagnostic features (HScore or 2016 MAS criteria for sJIA):
            fever + splenomegaly + <strong class="hld">â†‘â†‘ferritin (often &gt;684 ng/mL, frequently &gt;10,000)</strong> + cytopenias (â†“WBC + â†“PLT + â†“Hgb â€” paradoxical given inflammation) + â†‘LFTs + â†“fibrinogen + â†‘D-dimer + bone marrow showing hemophagocytosis</li>
          <li class="crit">Key paradox: <strong class="hld">ESR falls</strong> (fibrinogen is consumed â†’ clotting cascade activated â†’ ESR falsely low); CRP remains elevated â€” falling ESR in active sJIA = red flag for MAS</li>
          <li class="imp">Treatment: high-dose IV methylprednisolone; cyclosporine A (calcineurin inhibitor â€” first add-on); anakinra (IL-1i) increasingly used; etoposide in refractory; IVIG; treat underlying trigger (antiviral if EBV)</li>
        </ul>
        <div class="mnemonic">MAS = Massive Ferritin + falling ESR + Falling counts = EMERGENCY â†’ High-dose steroids STAT</div>
      </div>
    </div>

    <!-- CH 208 -->
    <div class="chapter-card" data-keywords="Kawasaki disease fever conjunctivitis lip changes strawberry tongue rash cervical lymphadenopathy coronary artery aneurysm IVIG aspirin echocardiogram incomplete">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 208</span>
        <span class="ch-title">Kawasaki Disease</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span><span class="tag tag-vasc">Vasculitis</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Most common cause of <strong class="hld">acquired heart disease</strong> in children in developed countries; medium-vessel vasculitis; unknown etiology; peak age 6 monthsâ€“5 years; boys &gt; girls; Asian children highest incidence</li>
        </ul>
        <div class="sub-hdr">â–¸ Classic Diagnostic Criteria (Fever â‰¥5 days + â‰¥4 of 5):</div>
        <table class="t">
          <thead><tr><th>Criterion</th><th>Details</th><th>Notes</th></tr></thead>
          <tbody>
            <tr><td class="lbl3">Bilateral non-exudative conjunctival injection</td><td>Bilateral, painless, limbic sparing (spares area around iris)</td><td>Most common feature; usually bulbar conjunctivitis</td></tr>
            <tr><td class="lbl3">Oral changes</td><td>Erythematous/cracked lips, strawberry tongue, diffuse erythema of oropharyngeal mucosa</td><td>Cannot have pharyngeal exudate (then consider GAS)</td></tr>
            <tr><td class="lbl3">Rash</td><td>Polymorphous, non-vesicular; maculopapular, diffuse, or erythema multiforme-like; NOT bullous; often perineal accentuation</td><td>Perineal desquamation early; finger/toe desquamation late (periungual, 2â€“3 weeks)</td></tr>
            <tr><td class="lbl3">Cervical lymphadenopathy</td><td>Unilateral, â‰¥1 node &gt;1.5 cm; least common criterion (~50%)</td><td>Often tender; firm; unilateral</td></tr>
            <tr><td class="lbl3">Extremity changes</td><td>Erythema of palms/soles, indurative edema of hands/feet (acute); periungual desquamation (subacute, weeks 2â€“3)</td><td>Desquamation is retrospective clue to diagnosis</td></tr>
          </tbody>
        </table>
        <ul class="key-points">
          <li class="crit"><strong class="hld">Incomplete Kawasaki</strong>: fever â‰¥5 days + fewer than 4 criteria; especially in infants &lt;6 months (highest coronary risk, fewest clinical criteria); diagnose by echo and labs (ESR/CRP elevated + â‰¥3 of: albumin â‰¤3, anemia, ALT elevated, platelets â‰¥450k after day 7, WBC â‰¥15k, urine WBCs â‰¥10/hpf)</li>
          <li class="crit"><strong class="hld">Coronary artery aneurysm (CAA)</strong>: main complication; develops in 15â€“25% without treatment, &lt;5% with IVIG; screen with echo at diagnosis, 1â€“2 wks, 4â€“6 wks after illness onset; giant aneurysm = &gt;8 mm â†’ thrombosis risk â†’ myocardial infarction</li>
        </ul>
        <div class="sub-hdr">â–¸ Treatment</div>
        <ul class="key-points">
          <li class="crit"><strong class="hld">IVIG 2 g/kg single infusion + Aspirin</strong> â†’ reduces coronary aneurysm from ~25% to &lt;5%</li>
          <li class="imp">Aspirin: high dose (80â€“100 mg/kg/day in 4 doses) during febrile phase â†’ switch to low dose (3â€“5 mg/kg/day) once afebrile; continue for 6â€“8 weeks if no CAA (or indefinitely if CAA present)</li>
          <li class="crit">IVIG resistance (~10â€“15%): consider second IVIG dose, infliximab (TNF-i), steroids (controversial), cyclosporine; high-risk: young age, high inflammatory markers, Asian ethnicity, Kobayashi score</li>
          <li class="note">Reye syndrome concern: aspirin use in viral illnesses; Kawasaki = exception to avoid-aspirin-in-children rule</li>
        </ul>
        <div class="mnemonic">Kawasaki: "CRASH + Fever 5 days" â†’ Conjunctivitis, Rash, Adenopathy (cervical), Strawberry tongue/lip changes, Hand/foot changes â†’ IVIG + Aspirin</div>
      </div>
    </div>

    <!-- CH 209 -->
    <div class="chapter-card" data-keywords="sarcoidosis Blau syndrome granuloma uveitis lymphadenopathy lupus pernio ACE serum angiotensin">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 209</span>
        <span class="ch-title">Sarcoidosis</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Sarcoidosis</strong>: multisystem granulomatous disease of unknown etiology; non-caseating granulomas; peak onset in adolescents and young adults in pediatrics</li>
          <li class="imp">Clinical: bilateral hilar lymphadenopathy (most common X-ray finding), pulmonary infiltrates, uveitis (25%), skin (erythema nodosum, lupus pernio), arthritis, peripheral lymphadenopathy, hepatosplenomegaly, hypercalcemia (granulomas produce 1,25-OH Vit D)</li>
          <li class="imp">Labs: â†‘serum ACE (angiotensin-converting enzyme) â€” neither sensitive nor specific; hypercalciuria/hypercalcemia; lymphopenia; â†‘Î³-globulins</li>
          <li class="note">Early-onset sarcoidosis in young children (&lt;5 yrs): triad of skin rash + arthritis + uveitis (resembles Blau syndrome â€” NOD2 mutation, familial form)</li>
          <li class="note">Diagnosis: biopsy showing non-caseating epithelioid granulomas + exclusion of other causes (especially TB â€” also causes granulomas but caseating)</li>
          <li class="note">Treatment: corticosteroids (systemic); MTX/azathioprine for steroid-sparing; hydroxychloroquine for skin; spontaneous remission in many</li>
        </ul>
        <div class="mnemonic">Sarcoidosis: non-caseating granulomas + Bilateral hilar adenopathy + elevated ACE + hypercalcemia</div>
      </div>
    </div>

    <!-- CH 210 -->
    <div class="chapter-card" data-keywords="vasculitis syndromes large medium small vessel GPA Wegener ANCA MPA polyarteritis nodosa Takayasu giant cell IgA HSP Henoch-SchÃ¶nlein PAN EGPA">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 210</span>
        <span class="ch-title">Vasculitis Syndromes</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span><span class="tag tag-vasc">Vasculitis</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <table class="t">
          <thead><tr><th>Classification</th><th>Disease</th><th>Key Features</th><th>Lab/Pathology</th><th>Treatment</th></tr></thead>
          <tbody>
            <tr>
              <td class="lbl" rowspan="2">Large Vessel</td>
              <td><strong class="hl">Takayasu Arteritis</strong></td>
              <td>Young females; aorta + major branches; arm claudication, blood pressure discrepancy between arms, absent pulses, hypertension (renal artery), carotidynia, stroke; constitutional symptoms</td>
              <td>â†‘ESR/CRP; CT/MR angiography (wall thickening â†’ stenosis); PET scan (active inflammation)</td>
              <td>High-dose steroids; MTX/MMF; TNF-i (infliximab); revascularization for critical ischemia</td>
            </tr>
            <tr>
              <td><strong class="hl">Giant Cell Arteritis (GCA)</strong></td>
              <td>Rare in children; temporal artery involved; jaw claudication; visual loss (ischemic optic neuropathy â€” EMERGENCY); headache; polymyalgia rheumatica</td>
              <td>â†‘ESR (&gt;50); temporal artery biopsy (skip lesions; must biopsy adequately)</td>
              <td>High-dose steroids immediately to prevent blindness; tocilizumab (FDA-approved)</td>
            </tr>
            <tr>
              <td class="lbl2" rowspan="2">Medium Vessel</td>
              <td><strong class="hl2">Kawasaki Disease</strong></td>
              <td>See Ch. 208</td>
              <td>See Ch. 208</td>
              <td>IVIG + aspirin</td>
            </tr>
            <tr>
              <td><strong class="hl2">Polyarteritis Nodosa (PAN)</strong></td>
              <td>Rare in children; necrotizing arteritis of medium vessels; renal, GI, skin, nerve involvement; livedo reticularis, mononeuritis multiplex, aneurysms on angiography; skin PAN (cutaneous only â€” benign)</td>
              <td>ANCA negative; angiography shows microaneurysms; biopsy; HBsAg (hepatitis B-associated PAN)</td>
              <td>Steroids + cyclophosphamide; antiviral if HBV-associated</td>
            </tr>
            <tr>
              <td class="lbl3" rowspan="3">Small Vessel (ANCA+)</td>
              <td><strong class="hlp">GPA (Granulomatosis with Polyangiitis) â€” formerly Wegener's</strong></td>
              <td>Upper airway (sinusitis, epistaxis, saddle-nose deformity, subglottic stenosis) + lower airway (pulmonary hemorrhage/nodules) + renal (rapidly progressive GN)</td>
              <td><strong class="hl">c-ANCA (anti-PR3)</strong> in ~90%; biopsies show granulomatous inflammation</td>
              <td>Steroids + cyclophosphamide (induction) or rituximab; maintenance MTX or azathioprine</td>
            </tr>
            <tr>
              <td><strong class="hlp">MPA (Microscopic Polyangiitis)</strong></td>
              <td>Renal (RPGN) + pulmonary hemorrhage; no upper airway involvement; no granulomas</td>
              <td><strong class="hl">p-ANCA (anti-MPO)</strong> in ~70%</td>
              <td>Same as GPA</td>
            </tr>
            <tr>
              <td><strong class="hlp">EGPA (Eosinophilic GPA) â€” Churg-Strauss</strong></td>
              <td>Asthma + eosinophilia + vasculitis; neuropathy, cardiac involvement</td>
              <td>p-ANCA (anti-MPO) in ~40%; eosinophilia</td>
              <td>Steroids Â± cyclophosphamide; mepolizumab (anti-IL-5)</td>
            </tr>
            <tr>
              <td class="lbl" rowspan="2">Small Vessel (ANCAâ€“)</td>
              <td><strong class="hl">IgA Vasculitis (Henoch-SchÃ¶nlein Purpura)</strong></td>
              <td><strong class="hld">Most common vasculitis in children</strong>; usually post-infectious (GAS, viral); IgA deposits in vessel walls; 4 features: palpable purpura (buttocks/legs, non-thrombocytopenic) + arthritis/arthralgia + abdominal pain (intussusception, GI bleeding) + renal (hematuria, proteinuria)</td>
              <td>Normal platelets (distinguishes from thrombocytopenic purpura); IgA â†‘; skin biopsy: IgA deposits; urinalysis for renal involvement</td>
              <td>Usually self-limited; NSAIDs for arthritis; steroids for severe GI/orchitis; ACE inhibitor if persistent nephritis; IVIG/rituximab for severe renal</td>
            </tr>
            <tr>
              <td>Hypersensitivity Vasculitis</td>
              <td>Small vessel; often drug-induced or post-infection; leukocytoclastic vasculitis on biopsy; purpuric rash</td>
              <td>Leukocytoclastic vasculitis on skin biopsy</td>
              <td>Remove offending drug; supportive care</td>
            </tr>
          </tbody>
        </table>
        <div class="mnemonic">GPA = c-ANCA (PR3) = saddle nose + sinuses + lungs + kidneys | MPA = p-ANCA (MPO) = lungs + kidneys only (no upper airway, no granulomas)</div>
      </div>
    </div>

    <!-- CH 211 -->
    <div class="chapter-card" data-keywords="musculoskeletal pain fibromyalgia growing pains reflex sympathetic dystrophy CRPS amplified pain">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 211</span>
        <span class="ch-title">Musculoskeletal Pain Syndromes</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Growing pains</strong>: most common musculoskeletal pain in children (10â€“20%); bilateral, lower extremity (calf/thighs), occurs late evening/night, resolves by morning, NO joint swelling; normal exam and labs; reassurance + massage + ibuprofen at night</li>
          <li class="imp"><strong class="hl">Juvenile fibromyalgia</strong>: widespread musculoskeletal pain + fatigue + sleep disturbance + multiple tender points; no inflammation; girls &gt; boys; associated with anxiety, depression, school absenteeism; labs normal</li>
          <li class="note">Treatment of fibromyalgia: aerobic exercise (most important), cognitive behavioral therapy (CBT), sleep hygiene, amitriptyline; avoid opioids and excessive medications</li>
          <li class="imp"><strong class="hl2">Amplified Musculoskeletal Pain Syndrome (AMPS)</strong> / Complex Regional Pain Syndrome (CRPS): disproportionate pain + autonomic dysfunction (allodynia, skin color/temperature/hair changes, sweating); young females; often after minor injury; no organic cause; normal labs and imaging</li>
          <li class="note">AMPS/CRPS treatment: intensive physiotherapy (desensitization), CBT, interdisciplinary pain program; NOT rest or immobilization (worsens condition)</li>
        </ul>
        <div class="mnemonic">Growing pains: Bilateral + Lower leg + Night only + Normal exam = Benign; reassure parents</div>
      </div>
    </div>

    <!-- CH 212 -->
    <div class="chapter-card" data-keywords="chronic overlapping pain conditions POIC central sensitization headache IBS functional abdominal pain dysmenorrhea">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 212</span>
        <span class="ch-title">Chronic Overlapping Pain Conditions</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Chronic overlapping pain conditions (COPCs)</strong>: cluster of chronic pain disorders that co-occur and share pathophysiology (central sensitization); includes fibromyalgia, IBS, chronic daily headache, pelvic pain, TMJ disorder, interstitial cystitis</li>
          <li class="note">Pathophysiology: central sensitization â€” abnormal pain processing by CNS, not peripheral nociceptor activation; amplified pain signal, allodynia (pain from non-painful stimuli), hyperalgesia</li>
          <li class="note">Often co-occur with anxiety, depression, PTSD, ACEs (adverse childhood experiences); biopsychosocial model essential</li>
          <li class="note">Management: interdisciplinary pain team, CBT, graded aerobic exercise, sleep hygiene; minimize unnecessary investigations/procedures that reinforce sick role; school reintegration goal</li>
        </ul>
      </div>
    </div>

    <!-- CH 213 -->
    <div class="chapter-card" data-keywords="miscellaneous arthritis sarcoid arthropathy leukemia arthritis transient synovitis Lyme disease pigmented villonodular synovitis hemophiliac arthropathy">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 213</span>
        <span class="ch-title">Miscellaneous Conditions Associated with Arthritis</span>
        <div class="ch-tags"><span class="tag tag-auto">Rheum</span><span class="tag tag-inf">Infection</span></div>
        <span class="ch-toggle">âŒ„</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit"><strong class="hld">Leukemia mimicking JIA</strong>: childhood ALL can present with bone pain, arthralgia, arthritis BEFORE the diagnosis of leukemia is established; red flags that suggest leukemia rather than JIA: bone pain out of proportion to joint findings, night pain, lymphadenopathy, hepatosplenomegaly, â†“CBC (cytopenias), LDH elevated, uric acid elevated, pain that wakes from sleep â†’ check CBC, LDH, uric acid BEFORE diagnosing JIA</li>
          <li class="imp"><strong class="hl">Transient synovitis of the hip</strong>: most common cause of acute hip pain in children 3â€“8 yrs; self-limited; distinguishing from septic arthritis (Kocher criteria): fever + non-weight-bearing + ESR &gt;40 + WBC &gt;12,000 â†’ if all 4 present, high probability septic arthritis â†’ surgical drainage</li>
          <li class="imp"><strong class="hl2">Lyme arthritis</strong>: caused by Borrelia burgdorferi; most common late manifestation; oligoarticular (knee most common), large joint; intermittent; after tick bite in endemic area; diagnose with Lyme ELISA + Western blot; treat oral doxycycline (children â‰¥8 yrs) or amoxicillin (&lt;8 yrs); 4 weeks</li>
          <li class="note"><strong class="hl">Hemophilic arthropathy</strong>: recurrent hemarthrosis in hemophilia A/B â†’ chronic synovitis â†’ cartilage destruction; knee, ankle, elbow most common; prevent with factor replacement; treat acute hemarthrosis with factor infusion + rest</li>
          <li class="note">Pigmented villonodular synovitis (PVNS): benign synovial proliferation; monoarticular (knee); bloody synovial fluid; treat with synovectomy Â± imatinib (CSF1R inhibitor)</li>
        </ul>
        <div class="mnemonic">Leukemia masking as JIA: Bone pain + Night pain + â†‘LDH + Cytopenias â†’ Check CBC before calling it JIA!</div>
      </div>
    </div>

  </div><!-- end chapters-grid -->

  <div class="footer">
    <span>Nelson Textbook of Pediatrics Â· 22nd Ed. Â· 2024</span>
    <span>Part XIV: Chapters 194â€“213</span>
  </div>

</div><!-- end pw -->

<script>
  let openedChapters = new Set();
  const TOTAL = 20;

  function toggleCard(header) {
    const card = header.parentElement;
    const wasOpen = card.classList.contains('open');
    card.classList.toggle('open');
    const chNum = card.querySelector('.ch-num').textContent;
    if (!wasOpen) openedChapters.add(chNum);
    updateProgress();
  }

  function updateProgress() {
    const pct = Math.min((openedChapters.size / TOTAL) * 100, 100);
    document.getElementById('progressFill').style.width = pct + '%';
    document.getElementById('progressText').textContent = `${openedChapters.size} / ${TOTAL} opened`;
  }

  function filterChapters() {
    const q = document.getElementById('searchInput').value.toLowerCase().trim();
    const cards = document.querySelectorAll('.chapter-card');
    let visible = 0;
    cards.forEach(card => {
      const match = !q || card.textContent.toLowerCase().includes(q) || (card.dataset.keywords||'').toLowerCase().includes(q);
      card.classList.toggle('hidden', !match);
      if (match) visible++;
    });
    document.getElementById('chapterCount').textContent = q
      ? `${visible} result${visible !== 1 ? 's' : ''}`
      : `${TOTAL} chapters`;
  }

  document.addEventListener('keydown', e => {
    if (e.ctrlKey && e.key === 'e') {
      e.preventDefault();
      document.querySelectorAll('.chapter-card:not(.open)').forEach(c => {
        c.classList.add('open');
        openedChapters.add(c.querySelector('.ch-num').textContent);
      });
      updateProgress();
    }
  });
</script>
</body>
</html>
